Roivant Chief Executive Officer Matt Gline expects the FDA to approve the launch of a drug used to fight a debilitating skin disease. He says the drug should be on the market by September. He speaks on "Bloomberg Open Interest." (Source…
View original source — Bloomberg ↗

